Tag Archive for: setanaxib

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

/in

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo.  The trial evaluated setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC) and elevated liver stiffness. The […]

Read more

Calliditas provides setanaxib patent update

/in

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer.”  The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering […]

Read more